Tau biology, biomarkers, and therapeutics
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-10 · 11 (4)
DOI: 10.1002/trc2.70165 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 21.10.2025. Verfasst von Bess Frost und 24 weiteren Autor:innen. Beteiligte Einrichtung: Center for Alzheimer's Disease Research Department of Molecular Biology Cellular Biology and Biochemistry Brown University Providence Rhode Island US…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. The Fall 2024 Alzheimer's Association Research Roundtable convened experts from academia, industry, National Institutes of Health (NIH), and the United States Food and Drug Administration (FDA) to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Discussions addressed the integration of tau biomarkers into the 2024 Revised Diagnostic Criteria for AD, updates to amyloid and tau positron emission tomography (PET) imaging, and modeling of biomarker trajectories. Presenters highlighted tau‐targeting therapeutics including antisense oligonucleotides, monoclonal antibodies, and small molecules, alongside innovations in drug delivery. The interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials were key themes. Regulatory insights facilitated discussions on drug approval pathways. The meeting highlighted the rapid evolution of tau research and emphasized opportunities to improve diagnostics, trial design, and treatment strategies in AD. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. Discussions addressed the integration of tau biomarkers into the 2024 revised diagnostic criteria for AD, updates to amyloid and tau PET imaging, modeling of biomarker trajectories, tau‐targeting therapeutics, and interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Alzheimer's Disease Research Department of Molecular Biology Cellular Biology and Biochemistry Brown University Providence Rhode Island USA.
- Enigma Biomedical Group Knoxville Tennessee USA.
- Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA.
- Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
- Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
- Curie.Bio. Boston Massachusetts USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Frost, B., Kolb, H., Algeciras-Schimnich, A., Betthauser, T. J., DeVos, S., Edelmayer, R. M., Elwood, F., Fleisher, A. S., Henley, D., Horie, K., Hyman, B., Kreisl, W. C., Kulic, L., Leuzy, A., Palma, J. A., Parmentier-Batteur, S., Patru, M. M., Rabinovici, G. D., Reyderman, L., …, & Weber, C. J. (2025). Tau biology, biomarkers, and therapeutics. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(4). https://doi.org/10.1002/trc2.70165
Vancouver
Frost B, Kolb H, Algeciras-Schimnich A, Betthauser TJ, DeVos S, Edelmayer RM, et al. Tau biology, biomarkers, and therapeutics. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(4). doi:10.1002/trc2.70165
BibTeX
@article{Frost2025,
author = {Frost, Bess and Kolb, Hartmuth and Algeciras-Schimnich, Alicia and Betthauser, Tobey J and DeVos, Sarah and Edelmayer, Rebecca M and Elwood, Fiona and Fleisher, Adam S and Henley, David and Horie, Kanta and Hyman, Bradley and Kreisl, William Charles and Kulic, Luka and Leuzy, Antoine and Palma, Jose-Alberto and Parmentier-Batteur, Sophie and Patru, Maria-Magdalena and Rabinovici, Gil D and Reyderman, Larisa and Sperling, Reisa A and Van Der Geyten, Serge and Wildsmith, Kristin R and Mahinrad, Simin and Carrillo, Maria C and Weber, Christopher J},
title = {Tau biology, biomarkers, and therapeutics},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2025},
volume = {11},
number = {4},
doi = {10.1002/trc2.70165}
}
EUVIMED